BioCryst Pharmaceuticals Inc. (BCRX)

3.64
0.04 1.11
NASDAQ : Health Technology
Prev Close 3.60
Open 3.66
Day Low/High 3.57 / 3.86
52 Wk Low/High 2.80 / 9.95
Volume 1.16M
Avg Volume 2.05M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 397.13M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioCryst Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2011 Financial Results

BioCryst Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2011 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter and nine months ended September 30, 2011.

BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted As A Late-Breaker Oral Presentation At The ACR/ARHP 2011 Annual Scientific Meeting

BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted As A Late-Breaker Oral Presentation At The ACR/ARHP 2011 Annual Scientific Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically...

BioCryst Pharmaceuticals To Announce Third Quarter 2011 Financial Results On November 2, 2011

BioCryst Pharmaceuticals To Announce Third Quarter 2011 Financial Results On November 2, 2011

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2011 financial results will be released on Wednesday, November 2, 2011.

Biocryst's Gout Drug Fails to Impress

Biocryst's Gout Drug Fails to Impress

Biocryst announces positive mid-stage study results for its gout drug BCX4208 but the drug looks far weaker than its competition.

BioCryst Announces Positive Top-Line Results From BCX4208 Phase 2B Gout Study In Patients Not Responding To Allopurinol Alone

BioCryst Announces Positive Top-Line Results From BCX4208 Phase 2B Gout Study In Patients Not Responding To Allopurinol Alone

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced positive top-line results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in gout patients who had failed to reach the...

BioCryst To Present New Peramivir Data At The 51st Annual ICAAC Meeting

BioCryst To Present New Peramivir Data At The 51st Annual ICAAC Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.

BioCryst To Present At Three Upcoming Investor Conferences

BioCryst To Present At Three Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present a corporate summary and an update regarding the Company’s clinical programs at the...

Dendreon's Blowup Spreads Across Biotech

Dendreon's Blowup Spreads Across Biotech

Investors are selling biotech stocks broadly Thursday following Dendreon's Provenge shortfall.

BioCryst Provides Corporate Update And Reports Second Quarter 2011 Financial Results

BioCryst Provides Corporate Update And Reports Second Quarter 2011 Financial Results

Please replace the release with the following corrected version.

BioCryst Pharmaceuticals To Announce Second Quarter 2011 Financial Results On August 4, 2011

BioCryst Pharmaceuticals To Announce Second Quarter 2011 Financial Results On August 4, 2011

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its second quarter 2011 financial results will be released on Thursday, August 4, 2011.

Kenneth Lee Appointed To BioCryst Pharmaceuticals’ Board Of Directors

Kenneth Lee Appointed To BioCryst Pharmaceuticals’ Board Of Directors

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Kenneth B.

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the...

BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual...

BioCryst Pharmaceuticals Announces Appointment Of Thomas Staab As Its Next Chief Financial Officer

BioCryst Pharmaceuticals Announces Appointment Of Thomas Staab As Its Next Chief Financial Officer

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Mr.

BioCryst Provides Corporate Update And Reports First Quarter 2011 Financial Results

BioCryst Provides Corporate Update And Reports First Quarter 2011 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2011.

BioCryst Pharmaceuticals Announces Changes To Its Board Of Directors

BioCryst Pharmaceuticals Announces Changes To Its Board Of Directors

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Peder Jensen, M.

BioCryst To Present At Bank Of America Merrill Lynch Healthcare Conference

BioCryst To Present At Bank Of America Merrill Lynch Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst, plans to provide a corporate summary and update regarding the Company’s ...

BioCryst Pharmaceuticals To Announce First Quarter 2011 Financial Results On May 4, 2011

BioCryst Pharmaceuticals To Announce First Quarter 2011 Financial Results On May 4, 2011

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its first quarter 2011 financial results will be released on Wednesday, May 4, 2011.

BioCryst To Present New BCX4208 Gout Results At The Annual European Congress Of Rheumatology

BioCryst To Present New BCX4208 Gout Results At The Annual European Congress Of Rheumatology

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European...

BioCryst Announces Close Of $30 Million Financing Transaction Related To Future RAPIACTA® Payments

BioCryst Announces Close Of $30 Million Financing Transaction Related To Future RAPIACTA® Payments

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has closed a $30 million financing transaction to monetize certain future RAPIACTA ® ( peramivir) payments from Shionogi & Co.

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the...

BioCryst Awarded Additional $55.0 Million By The U.S. Department Of Health & Human Services To Complete Peramivir Phase 3 Program

BioCryst Awarded Additional $55.0 Million By The U.S. Department Of Health & Human Services To Complete Peramivir Phase 3 Program

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that it has been awarded a $55.

BioCryst Provides Corporate Update And Reports Fourth Quarter And Full Year 2010 Financial Results

BioCryst Provides Corporate Update And Reports Fourth Quarter And Full Year 2010 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2010.

BioCryst Pharmaceuticals To Announce Fourth Quarter And Full Year 2010 Financial Results On February 10, 2011

BioCryst Pharmaceuticals To Announce Fourth Quarter And Full Year 2010 Financial Results On February 10, 2011

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its fourth quarter and full year 2010 financial results will be released on Thursday, February 10, 2011.

BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results And Provides A Clinical Program Update

BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results And Provides A Clinical Program Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced top-line results from one of its two Phase 3 studies of intravenous (i.

BioCryst To Present At J.P. Morgan Healthcare Conference

BioCryst To Present At J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst plans to provide a corporate summary and update regarding the Company’s clinical ...

BioCryst Initiates A Phase 2b Study Of BCX4208 As Add-on Therapy In Gout Patients Not Responding To Allopurinol Alone

BioCryst Initiates A Phase 2b Study Of BCX4208 As Add-on Therapy In Gout Patients Not Responding To Allopurinol Alone

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.

BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic Lymphocytic Leukemia At The 52nd Annual American Society Of Hematology Meeting

BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic Lymphocytic Leukemia At The 52nd Annual American Society Of Hematology Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data that confirms forodesine’s clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52 nd Annual...

BioCryst To Present New Data For BCX4208 Monotherapy At The 74th Annual American College Of Rheumatology (ACR) Scientific Meeting

BioCryst To Present New Data For BCX4208 Monotherapy At The 74th Annual American College Of Rheumatology (ACR) Scientific Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74 th ACR Scientific Meeting being held in...

BioCryst Awarded $1.1 Million In Grants For Qualifying Therapeutic Development Projects

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the Company had been awarded $1.

TheStreet Quant Rating: D- (Sell)